Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study
March 22 2021 - 2:45AM
Dow Jones News
By Cecilia Butini
Roche Holding AG said Monday that a Phase 3 study on its
monoclonal antibody drug Tecentriq met the primary endpoint of
providing disease-free survival to lung cancer patients.
The Swiss pharmaceutical major said the drug showed a
statistically significant improvement in disease-free survival for
patients suffering non-small-cell lung cancer after surgery and
chemotherapy.
Tecentriq is already approved for five indications for different
types of lung cancer in markets around the world, Roche said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 22, 2021 02:30 ET (06:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
